Allozymes
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$255k | Seed | ||
N/A | Seed | ||
* | $5.0m | Seed | |
N/A | Seed | ||
* | N/A | Series A | |
* | $15.0m | Series A | |
Total Funding | CAD27.6m |
Recent News about Allozymes
EditAllozymes is a biotechnology company that leverages its proprietary microfluidics technology to rapidly develop novel enzymes, transforming the way industries manufacture complex natural products. The company serves clients across various sectors, including pharmaceuticals, cosmetics, and food and beverage. Operating in the enzyme engineering market, Allozymes collaborates with GenScript to provide comprehensive protein engineering services. The business model revolves around offering screening services and constructing mutant libraries for diverse applications. Revenue is generated through service contracts and partnerships with industry players.
Keywords: enzyme development, microfluidics, biotechnology, pharmaceuticals, cosmetics, food and beverage, protein engineering, sustainable manufacturing, mutant libraries, GenScript.